Diagnosis & Disease Information

Synribo Approved for Chronic Myeloid Leukemia

Teva Pharmaceuticals announced that the FDA has approved Synribo (omacetaxine mepesuccinate) for Injection to treat adult patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs).

Next post in Hematologic Cancers